 Life Science Investor Mandates
(Mar. 9
- Mar. 15)
|
|
|
|
|
Invests in Highly Innovative Early Stage Medtech, Diagnostics and Healthcare IT
|
Raises New Fund, Seeks Healthcare IT Opportunities
|
|
Invests in Preclinical Drugs in Oncology and Chronic Diseases
|
|
Seeks Technology-Driven Medical Devices
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
|
 |
 |
|
An interview with Life Science Nation's CEO Dennis Ford regarding the up and coming Redefining Early Stage Investments conference series
- By Ying Tam
|
|
|
Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS:
Dennis, what is the key differentiator of the Redefining Early Stage Investments (RESI) Conference?
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series:
The sweet spot. RESI is the only "dedicated" early stage global investor conference out there that I can find. On another note, we actually deliver 10 categories of early stage investors. Also, to your point, RESI is unique and the only one that goes across the silos of Drugs, Devices, Diagnostics and Healthcare IT, which is one of the reasons why JLABS has stuck with RESI as title sponsor for three years now. Many investors have multiple investment mandates covering multiple silo's in the life science arena.
Ying Tam:
Who does the RESI Conference compete with?
Dennis Ford: There are other conferences that we share the marketplace with. RESI is focused on Preclinical, Phase I and Phase II funding strictly. Other conferences tend to be more general and more focused on Phase III and commercialization centric in their content and RESI has 16 panels of dedicated to early stage investment content aimed precisely at fundraising CEOs and scientist-entrepreneurs...
|
|
|
By Sarah Mortimer, MaRS Discovery District
 With venture capital and private equity investing hitting levels not seen since the dot-com boom, Canada is increasingly drawing foreign investors scoping the latest innovations. One of their areas of focus is the country's medical device and equipment sector, which is now ranked ninth globally, according to Canada's federal department of Foreign Affairs, Trade and Development.
"The medical devices sector in Canada is one to watch," says Dan Mathers, investment director at the MaRS Investment Accelerator Fund (IAF), noting that the same government report estimates the sector's worth at $6.8 billion, with additional exports totaling $1.9 billion. "Canada has always had a very strong ecosystem for driving innovation in health sciences, particularly in medical imaging, equipment and devices. The vision here is big...
|
|
|
 Healthcare IT entrepreneurs, as opposed to biotech/medtech entrepreneurs, enjoy some favorable realities when it comes to successfully launching and sustaining a new venture. However, even though software and healthcare IT companies require far less capital than a biopharmaceutical product or medical device to get up and running, investors tend to place an emphasis on market penetration and traction, often the rate limiting step for these startups. A key to overcoming this hurdle is healthy ecosystem with innovative institutions willing to put programs in place to help new digital health technologies enter the marketplace and refine their product.
Canada is embracing digital health and the impact it can have on the public, patients and the healthcare system at large. Toronto, as the epicenter of Canadian healthcare and innovation, is naturally working to catalyze venture creation in healthcare IT and will host the RESI conference and a panel of venture investors active in the space.
The session will feature the following investors:
- Sam Ifergan, President & Managing Partner, iGan Partners
- Aaron Nelson, General Partner, dRx Capital
- Richard Osborn, Managing Partner, TELUS Ventures
- Samer Abughannam, Vice President, Persistence Capital Partners
- Sid Paquette, Managing Director, OMERS Ventures
|
|
|
|
|
|
